Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: Review and future prospects

Yukai He, Yuan Hong, Gerald J. Mizejewski

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Activation of a patient's immune system offers an attractive approach to prevent and treat hepatocellular carcinoma (HCC). However, the antitumor efficacy of current HCC vaccines was weak owing to insufficient immune activation of targeting self/tumor antigens. We recently found that epitope-optimized α-fetoprotein effectively activated CD8 T cells and generated potent antitumor effects in the carcinogen-induced autochthonous HCC mouse model. We predict that the same antigen engineering approach of epitope-optimization will enable us to develop effective human vaccines to prevent HCC recurrence after liver resection. The engineered human HCC vaccines may also allow us to identify high-affinity T-cell receptors and antibodies that can be used to reprogram T cells to treat HCC tumors via adoptive transfer.

Original languageEnglish (US)
Pages (from-to)725-736
Number of pages12
JournalImmunotherapy
Volume6
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Fetal Proteins
Hepatocellular Carcinoma
Vaccines
Genes
Epitopes
T-Lymphocytes
Adoptive Transfer
Autoantigens
Neoplasm Antigens
T-Cell Antigen Receptor
Carcinogens
Immune System
Antigens
Recurrence
Antibodies
Liver
Neoplasms

Keywords

  • antigen engineering
  • cancer vaccine
  • epitope optimization
  • genetic immunization
  • hepatocellular carcinoma
  • immunotherapy
  • recombinant lentivector

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma : Review and future prospects. / He, Yukai; Hong, Yuan; Mizejewski, Gerald J.

In: Immunotherapy, Vol. 6, No. 6, 01.01.2014, p. 725-736.

Research output: Contribution to journalReview article

@article{ab2769b45f774fa6bd42e872d8330477,
title = "Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: Review and future prospects",
abstract = "Activation of a patient's immune system offers an attractive approach to prevent and treat hepatocellular carcinoma (HCC). However, the antitumor efficacy of current HCC vaccines was weak owing to insufficient immune activation of targeting self/tumor antigens. We recently found that epitope-optimized α-fetoprotein effectively activated CD8 T cells and generated potent antitumor effects in the carcinogen-induced autochthonous HCC mouse model. We predict that the same antigen engineering approach of epitope-optimization will enable us to develop effective human vaccines to prevent HCC recurrence after liver resection. The engineered human HCC vaccines may also allow us to identify high-affinity T-cell receptors and antibodies that can be used to reprogram T cells to treat HCC tumors via adoptive transfer.",
keywords = "antigen engineering, cancer vaccine, epitope optimization, genetic immunization, hepatocellular carcinoma, immunotherapy, recombinant lentivector",
author = "Yukai He and Yuan Hong and Mizejewski, {Gerald J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.2217/imt.14.46",
language = "English (US)",
volume = "6",
pages = "725--736",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma

T2 - Review and future prospects

AU - He, Yukai

AU - Hong, Yuan

AU - Mizejewski, Gerald J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Activation of a patient's immune system offers an attractive approach to prevent and treat hepatocellular carcinoma (HCC). However, the antitumor efficacy of current HCC vaccines was weak owing to insufficient immune activation of targeting self/tumor antigens. We recently found that epitope-optimized α-fetoprotein effectively activated CD8 T cells and generated potent antitumor effects in the carcinogen-induced autochthonous HCC mouse model. We predict that the same antigen engineering approach of epitope-optimization will enable us to develop effective human vaccines to prevent HCC recurrence after liver resection. The engineered human HCC vaccines may also allow us to identify high-affinity T-cell receptors and antibodies that can be used to reprogram T cells to treat HCC tumors via adoptive transfer.

AB - Activation of a patient's immune system offers an attractive approach to prevent and treat hepatocellular carcinoma (HCC). However, the antitumor efficacy of current HCC vaccines was weak owing to insufficient immune activation of targeting self/tumor antigens. We recently found that epitope-optimized α-fetoprotein effectively activated CD8 T cells and generated potent antitumor effects in the carcinogen-induced autochthonous HCC mouse model. We predict that the same antigen engineering approach of epitope-optimization will enable us to develop effective human vaccines to prevent HCC recurrence after liver resection. The engineered human HCC vaccines may also allow us to identify high-affinity T-cell receptors and antibodies that can be used to reprogram T cells to treat HCC tumors via adoptive transfer.

KW - antigen engineering

KW - cancer vaccine

KW - epitope optimization

KW - genetic immunization

KW - hepatocellular carcinoma

KW - immunotherapy

KW - recombinant lentivector

UR - http://www.scopus.com/inward/record.url?scp=84904621154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904621154&partnerID=8YFLogxK

U2 - 10.2217/imt.14.46

DO - 10.2217/imt.14.46

M3 - Review article

C2 - 25041030

AN - SCOPUS:84904621154

VL - 6

SP - 725

EP - 736

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 6

ER -